Skip to main content

Table 1 Numbers of randomized patients‡

From: Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features

Study

Placebo

SSRIa

Duloxetine

   

40 mg/db

60 mg QD

80 mg/dc

120 mg/dd

1

70 (80.0)

33 (72.7)

-

-

-

70 (77.1)

2

74 (73.0)

37 (86.5)

-

-

-

82 (69.5)

3

90 (55.6)

89 (64.0)

91 (62.6)

-

84 (60.7)

-

4

89 (66.3)

87 (63.2)

86 (72.1)

-

91 (69.2)

-

5

121 (69.4)

-

-

122 (63.1)

-

-

6

139 (62.6)

-

-

128 (62.5)

-

-

7

93 (66.7)

86 (68.6)

-

-

95 (65.3)

93 (66.7)

8

99 (67.7)

97 (69.1)

-

-

93 (71.0)

103 (66.0)

TOTAL

775 (67.0)

429 (68.5)

1138 (66.7)

  1. ‡ Data presented in the form T (% M), where T = total number of patients, % M = percentage of patients with melancholic features
  2. a. SSRI in Studies 1 and 2 is fluoxetine (20 mg QD). SSRI in Studies 3, 4, 7, and 8 is paroxetine (20 mg QD).
  3. b. Administered 20 mg twice-daily (BID)
  4. c. Administered 40 mg BID
  5. d. Administered 60 mg BID. Studies 1 and 2 incorporated a forced titration from 20 mg BID to 60 mg BID.
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us